Fluvoxamine versus desipramine in elderly patients with major depression: A double-blind comparison

Tourigny-Rivard, M.; Nair, Navin; Vincent, Pol

doi:10.1016/0924-977x(96)83081-1

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total dropout rate was relatively high, ranging from 0% (de Wilde 1983; Mendonca Lima 1997; Miller 2001; Tourigny-Rivard 1996) to 59 % (Claghorn 1996). There were twenty-seven studies (27/ 54, 50%) where the total dropout rates were more than 20%.…”

Section: Resultsmentioning

confidence: 99%

“…Sixteen studies reported this outcome. Among them, imputation methods were used for 11 studies (Claghorn 1996; de Wilde 1983; Feighner 1989; Guy 1984; Harris 1991a; Lydiard 1989; March 1990; Mullin 1988; Rahman 1991; Remick 1994; Tourigny-Rivard 1996). There was no strong evidence that fluvoxamine was either superior or inferior to TCAs except desipraminein terms of this dichotomous outcome in head-to-head comparisons.…”

Section: Resultsmentioning

confidence: 99%

“…Fluvoxamine was found to be more effective than desipramine based on one trial (OR: 4.50, 95% CI 1.31 to 15.42, P=0.02; 1 trial, 47 participants) (Tourigny-Rivard 1996); this small study did not report the actual number of patients who experienced remission, so we converted HRSD data expressed as mean and SD into the number of remitted patients, according to the validated imputation method (Furukawa 2005) (Figure 6).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Fluvoxamine versus other anti-depressive agents for depression

Omori

Watanabe

Nakagawa

et al. 2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Fluvoxamine, one of the oldest selective serotonin reuptake inhibitors (SSRIs), is prescribed to patients with major depression in many countries. Several studies have previously reviewed the efficacy and tolerability of fluvoxamine for the treatment of major depression. However, these reviews are now outdated. Objectives Our objective is to evaluate the effectiveness, tolerability and side effect profile of fluvoxamine for major depression in comparison with other anti-depressive agents, including tricyclics (TCAs), heterocyclics, other SSRIs, SNRIs, other newer agents and other conventional psychotropic drugs. Search methods We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register. Trial databases and ongoing trial registers in North America, Europe, Japan and Australia, were handsearched for randomised controlled trials. We checked reference lists of the articles included in the review, previous systematic reviews and major textbooks of affective disorder for published reports and citations of unpublished research. The date of last search was 31 August 2008. Selection criteria We included all randomised controlled trials, published in any language, that compared fluvoxamine with any other active antidepressants in the acute phase treatment of major depression. Data collection and analysis Two independent review authors inspected citations and abstracts, obtained papers, extracted data and assessed the risk of bias of included studies. We analysed dichotomous data using odds ratios (ORs) and continuous data using the standardised mean difference (SMD). A random effects model was used to combine studies. Main results A total of 54 randomised controlled trials (n = 5122) were included. No strong evidence was found to indicate that fluvoxamine was either superior or inferior to other antidepressants regarding response, remission and tolerability. However, differing side effect profiles were evident, especially with regard to gastrointestinal side effects of fluvoxamine when compared to other antidepressants. For example, fluvoxamine was generally associated with a higher incidence of vomiting/nausea (versus imipramine, OR 2.23, CI 1.59 to 3.14; versus clomipramine, OR 2.13, CI 1.06 to 4.27; versus amitriptyline, OR 2.86, CI 1.31 to 2.63). Authors’ conclusions We found no strong evidence that fluvoxamine was either superior or inferior to any other antidepressants in terms of efficacy and tolerability in the acute phase treatment of depression. However, differing side effect profiles were evident. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations, including these differences in side effect profiles.

show abstract